Advertisement
INCY vs LCID
Which Stock Would AI Choose? Incyte (INCY) vs. Lucid Group (LCID) Stock Comparison
Key Takeaways
- INCY is a profitable, large-cap biopharmaceutical company with rising revenue and an expanding pipeline; LCID is a smaller, pre-profit electric vehicle (EV) maker managing heavy cash burn.
- Recent market activity has favored INCY, which trades near its 52-week high, while LCID remains sharply lower over the trailing year despite periodic rebounds.
- The two companies operate in entirely different sectors—healthcare versus consumer discretionary/automotive—so their risk profiles and growth drivers are not directly comparable.
- INCY recently raised its full-year revenue guidance after a favorable settlement; LCID has pivoted to a $1.4 billion cash-flow improvement plan and restructuring review.
- Investors seeking trend stability and profitability may find INCY more aligned with their criteria, while LCID represents a higher-risk turnaround story.
Introduction
Comparing INCY (Incyte Corporation) and LCID (Lucid Group, Inc.) brings together two very different investment profiles. One is an established biopharmaceutical company generating substantial profits from approved medicines; the other is a young electric-vehicle maker still working toward profitability amid an industry-wide slowdown. This stock comparison is most relevant to investors and traders weighing steady, earnings-backed growth against a speculative, catalyst-driven turnaround. Understanding the relative performance, market positioning, and risk factors of each name can help clarify which type of exposure better fits a given strategy in the current environment.
INCY Overview and Recent Performance
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company that discovers and commercializes treatments for cancer, blood disorders, and immune-mediated diseases. Its flagship product, Jakafi (ruxolitinib), anchors a commercial portfolio that also includes Opzelura cream, Niktimvo, Monjuvi/Minjuvi, and Zynyz. Recent market activity has been notably constructive: INCY shares have traded near their 52-week high and remained above both their 50-day and 200-day moving averages, reflecting sustained upward momentum and comparatively low volatility (a beta below 1.0).
In recent quarters, revenue growth has accelerated on strong demand across the portfolio, and management raised its full-year revenue guidance after reaching a settlement with the Centers for Medicare & Medicaid Services (CMS) over rebate criteria for Opzelura. The company has also advanced a deep late-stage pipeline and strengthened its cash position. The main longer-term concern cited by analysts is the expected loss of exclusivity for Jakafi later this decade, which Incyte is working to offset through new launches and pipeline diversification.
LCID Overview and Recent Performance
Lucid Group, Inc., based in Newark, California, designs and manufactures luxury electric vehicles, including the Air sedan and Gravity SUV, while developing a lower-cost midsize platform. Recent market activity has been volatile: LCID shares have declined sharply on a trailing-year basis, even as company-specific announcements have triggered intermittent rallies. The stock remains well below its highs, reflecting investor caution around execution and cash burn.
Recent quarters showed rising revenue driven by higher deliveries and an improved product mix, but gross margins remained deeply negative and losses widened. In response, Lucid engaged restructuring advisor AlixPartners and outlined a $1.4 billion cash-flow improvement plan spanning inventory reduction, lower capital spending, and workforce cuts. The company also announced an expanded partnership with European mobility platform Bolt to deploy autonomous-ready Lucid vehicles, complementing its robotaxi work with Uber and Nuro. These steps are aimed at stabilizing the business, but profitability remains a longer-term objective.
Trending AI Robots
For traders who prefer a data-driven approach, Tickeron curates a dedicated Trending AI Robots section. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the strongest performers—those best suited to current market conditions—earn a place in this featured list. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers it trades, giving users a range of approaches rather than a one-size-fits-all signal. Reviewing the curated robots can help traders see how AI models are currently positioning across names like INCY and LCID. Explore the Trending AI Robots page to see which strategies are leading right now.
Head-to-Head Comparison
The clearest contrast between these two stocks is financial maturity. INCY generates positive net income, holds a multi-billion-dollar cash balance, and trades at a market capitalization roughly fifteen times larger than LCID. Its risks center on pipeline execution and a future patent cliff, which are longer-dated and partially mitigated by diversification. LCID, by contrast, is scaling production while absorbing negative gross margins and ongoing operating losses, making capital efficiency and demand for EVs its primary near-term challenges.
Sector exposure also differs sharply. Incyte sits in healthcare, historically viewed as more defensive and less tied to discretionary consumer spending. Lucid operates in the automotive/EV market, where sentiment is influenced by interest rates, consumer demand, and competition. On recent momentum, INCY has demonstrated steadier relative performance, while LCID has been event-driven, with sharper moves on restructuring and partnership headlines. These differences make the two names complementary as illustrations of distinct risk profiles rather than direct competitors.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor INCY in the current environment. The stock exhibits more consistent trend characteristics—trading above key moving averages with lower volatility—alongside positive earnings, a rising revenue outlook, and a supportive balance sheet. LCID, while carrying meaningful catalysts such as its robotaxi partnerships and restructuring plan, presents a less stable trend profile with negative margins, heavy cash burn, and higher event-driven volatility. Accordingly, the AI's positioning would probably tilt toward INCY for trend consistency and relative stability, while treating LCID as a higher-risk, catalyst-dependent opportunity that requires confirmation before warranting greater exposure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a StrongBuy and LCID is a Buy.
INCY | LCID | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 43 | 100 | |
SMR RATING 1..100 | 33 | 100 | |
PRICE GROWTH RATING 1..100 | 47 | 89 | |
P/E GROWTH RATING 1..100 | 65 | 50 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LCID's Valuation (50) in the null industry is somewhat better than the same rating for INCY (88) in the Biotechnology industry. This means that LCID’s stock grew somewhat faster than INCY’s over the last 12 months.
INCY's Profit vs Risk Rating (43) in the Biotechnology industry is somewhat better than the same rating for LCID (100) in the null industry. This means that INCY’s stock grew somewhat faster than LCID’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is significantly better than the same rating for LCID (100) in the null industry. This means that INCY’s stock grew significantly faster than LCID’s over the last 12 months.
INCY's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for LCID (89) in the null industry. This means that INCY’s stock grew somewhat faster than LCID’s over the last 12 months.
LCID's P/E Growth Rating (50) in the null industry is in the same range as INCY (65) in the Biotechnology industry. This means that LCID’s stock grew similarly to INCY’s over the last 12 months.
| INCY | LCID | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 62% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 62% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 59% | 1 day ago 90% |
| MACD ODDS (%) | 7 days ago 58% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 59% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 90% |
| Advances ODDS (%) | 20 days ago 65% | 15 days ago 78% |
| Declines ODDS (%) | 1 day ago 54% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 63% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 57% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green while LCID’s FA Score has 0 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- LCID’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while LCID’s TA Score has 5 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 6 bearish.
- LCID’s TA Score: 5 bullish, 3 bearish.
Price Growth
INCY (@Biotechnology) experienced а -8.56% price change this week, while LCID (@Motor Vehicles) price change was +6.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.37%. For the same industry, the average monthly price growth was -13.88%, and the average quarterly price growth was -3.26%.
The average weekly price growth across all stocks in the @Motor Vehicles industry was -4.15%. For the same industry, the average monthly price growth was -17.62%, and the average quarterly price growth was -25.89%.
Reported Earning Dates
INCY is expected to report earnings on Nov 03, 2026.
LCID is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Biotechnology (-3.37% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Motor Vehicles (-4.15% weekly)Automobiles continue to be arguably the most popular form of passenger travel in the U.S., and major automobile makers have revenues and market capitalizations running into multi-billions. In recent years, the industry has been experiencing some path-breaking innovations like electric vehicles and self-driving technology. While there are long-standing companies like General Motors, Ford, and Toyota Motors operating in this space, there are also emerging/rapidly growing players like Tesla – which has had a major role in the growing popularity of the electric vehicle market. With technological advancements taking steam in the auto space, we’ve also witnessed collaborations (or talks of potential partnerships) of carmakers with tech behemoths like Google’s subsidiary, Waymo.
Advertisement
INCY and
Correlation & Price change
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with RPRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then RPRX could also see price increases.
| Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
|---|---|---|---|---|
| INCY | 100% | -1.01% | ||
| RPRX - INCY | 45% Loosely correlated | -0.87% | ||
| HALO - INCY | 43% Loosely correlated | -1.41% | ||
| VRTX - INCY | 40% Loosely correlated | -0.24% | ||
| AXON - INCY | 39% Loosely correlated | -0.37% | ||
| BMRN - INCY | 37% Loosely correlated | +0.63% | ||
More | ||||
LCID and
Correlation & Price change
A.I.dvisor indicates that over the last year, LCID has been loosely correlated with RIVN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if LCID jumps, then RIVN could also see price increases.
| Ticker / NAME | Correlation To LCID | 1D Price Change % | ||
|---|---|---|---|---|
| LCID | 100% | +0.97% | ||
| RIVN - LCID | 39% Loosely correlated | +2.10% | ||
| GP - LCID | 34% Loosely correlated | +0.12% | ||
| WKHS - LCID | 31% Poorly correlated | -0.67% | ||
| F - LCID | 31% Poorly correlated | +0.41% | ||
| TSLA - LCID | 30% Poorly correlated | +2.20% | ||
More | ||||